Berlin, Germany, July 12, 2016 --(PR.com
)-- Erin Keaney, Investigator III of Global Discovery Chemistry at Novartis Institutes for BioMedical Research, will discuss “Inhibitors of Vps34 Provide Chemical Tools to Modulate Autophagy in Vivo and Enable a Proteomics Strategy to Identify Autophagy Substrates” at GTCbio’s 11th Drug Design & Medicinal Chemistry to be held on September 12-13, 2016 in Boston, MA.
The autophagy process is an essential pathway utilized by cells to breakdown damaged cellular constituents and provide the cell with energy. A variety of diseases including cancer and neurodegeneration have been linked to the activation or inhibition of autophagy. In an effort to identify pharmacological agents to inhibit this process, Dr. Keaney’s group utilized a high-throughput screen of an essential component of this pathway, Vps34. Dr. Keaney will describe the optimization efforts leading to the development of a highly selective Vps34 inhibitor and tool capable of disrupting autophagy in vivo. Further interrogation of this pathway as a means to identify novel autophagy substrates was accomplished via ubiquitin-affinity proteomics.
This meeting will provide a forum for scientists across multiple disciplines, from both industry and academia, to connect and share complementary perspectives. We will discuss emerging target classes, advances in antibody drug conjugates and other methods for targeted drug delivery, new approaches in flow chemistry, and much more. In addition to scientific presentations, they will have dedicated times for networking among delegates.
Session topics include:
I. Advances in Addressing Traditional and New Target Classes
II. Targeting Protein-Protein Interactions
III. Methods for Target Identification
IV. New Opportunities for Computational Drug Design
V. Big Data in Medicinal Chemistry
For more information, please visit website: https://www.gtcbio.com/conferences/medicinal-chemistry-drug-design-overview
635 W. Foothill Blvd
Monrovia, CA 91016
Phone: (626) 256-6405
Fax: (626) 466-4433